| Primary |
| Convulsion |
38.8% |
| Epilepsy |
25.5% |
| Grand Mal Convulsion |
6.5% |
| Status Epilepticus |
5.0% |
| Convulsion Prophylaxis |
4.3% |
| Glioblastoma Multiforme |
3.2% |
| Chemotherapy |
2.4% |
| Product Used For Unknown Indication |
2.3% |
| Prophylaxis |
1.8% |
| Drug Use For Unknown Indication |
1.6% |
| Hypertension |
1.6% |
| Partial Seizures |
1.2% |
| Pneumonia Mycoplasmal |
1.1% |
| Ill-defined Disorder |
0.9% |
| Vomiting |
0.8% |
| Seizure |
0.7% |
| Complex Partial Seizures |
0.6% |
| Bipolar Disorder |
0.6% |
| Febrile Convulsion |
0.6% |
| Surgery |
0.6% |
|
| Toxicity To Various Agents |
12.3% |
| Convulsion |
12.0% |
| Toxic Epidermal Necrolysis |
8.1% |
| Drug Ineffective |
6.1% |
| Tremor |
6.1% |
| Vomiting |
5.8% |
| Therapeutic Agent Toxicity |
5.7% |
| Stevens-johnson Syndrome |
5.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.8% |
| Rash |
4.5% |
| Thrombocytopenia |
3.4% |
| Pyrexia |
3.2% |
| Drug Interaction |
3.1% |
| Mental Status Changes |
3.1% |
| Nystagmus |
3.1% |
| Medication Error |
2.8% |
| Status Epilepticus |
2.8% |
| Vision Blurred |
2.8% |
| Lethargy |
2.6% |
| Somnolence |
2.6% |
|
| Secondary |
| Epilepsy |
19.7% |
| Product Used For Unknown Indication |
19.4% |
| Convulsion |
19.3% |
| Drug Use For Unknown Indication |
13.3% |
| Status Epilepticus |
7.8% |
| Infantile Spasms |
3.7% |
| Grand Mal Convulsion |
3.7% |
| Glioblastoma Multiforme |
1.9% |
| Hypertension |
1.5% |
| Convulsion Prophylaxis |
1.2% |
| Lennox-gastaut Syndrome |
1.2% |
| Prophylaxis |
1.1% |
| Partial Seizures |
1.1% |
| Pneumonia Mycoplasmal |
0.9% |
| Suicide Attempt |
0.8% |
| Frontal Lobe Epilepsy |
0.7% |
| Bipolar Disorder |
0.7% |
| Depression |
0.7% |
| Foetal Exposure During Pregnancy |
0.6% |
| Urinary Tract Infection |
0.6% |
|
| Toxicity To Various Agents |
10.1% |
| Completed Suicide |
8.8% |
| Convulsion |
8.6% |
| Drug Ineffective |
7.0% |
| Stevens-johnson Syndrome |
6.7% |
| Toxic Epidermal Necrolysis |
6.2% |
| Vomiting |
5.9% |
| Status Epilepticus |
5.7% |
| Vision Blurred |
4.5% |
| Metabolic Acidosis |
4.1% |
| Death |
4.0% |
| Drug Interaction |
3.6% |
| Weight Decreased |
3.6% |
| Rash |
3.3% |
| Drug Toxicity |
3.1% |
| Grand Mal Convulsion |
3.1% |
| Tachycardia |
3.1% |
| Somnolence |
3.0% |
| Thrombocytopenia |
2.9% |
| Ophthalmoplegia |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.2% |
| Drug Use For Unknown Indication |
19.0% |
| Epilepsy |
17.1% |
| Convulsion |
8.6% |
| Prophylaxis |
4.7% |
| Hypertension |
3.5% |
| Status Epilepticus |
2.6% |
| Stem Cell Transplant |
2.4% |
| Prophylaxis Against Graft Versus Host Disease |
2.3% |
| Depression |
2.2% |
| Pain |
2.1% |
| Infection Prophylaxis |
1.8% |
| Grand Mal Convulsion |
1.6% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Convulsion Prophylaxis |
1.5% |
| Rheumatoid Arthritis |
1.2% |
| Hiv Infection |
1.0% |
| Multiple Myeloma |
0.9% |
| Acute Lymphocytic Leukaemia |
0.9% |
| Partial Seizures |
0.8% |
|
| Vomiting |
13.8% |
| Status Epilepticus |
8.4% |
| Convulsion |
7.2% |
| Epilepsy |
7.0% |
| Sepsis |
6.1% |
| Somnolence |
5.6% |
| Death |
4.7% |
| Respiratory Failure |
4.6% |
| Unresponsive To Stimuli |
4.6% |
| Drug Ineffective |
4.0% |
| Pneumonia |
3.8% |
| Urinary Tract Infection |
3.8% |
| Tachycardia |
3.7% |
| Weight Increased |
3.6% |
| White Blood Cell Count Decreased |
3.5% |
| Rash |
3.2% |
| Stomatitis |
3.2% |
| Weight Decreased |
3.2% |
| Tremor |
2.9% |
| Venoocclusive Liver Disease |
2.9% |
|
| Interacting |
| Epilepsy |
26.4% |
| Convulsion |
16.8% |
| Grand Mal Convulsion |
10.9% |
| Partial Seizures |
4.8% |
| Drug Use For Unknown Indication |
4.2% |
| Complex Partial Seizures |
3.2% |
| Mineral Supplementation |
3.2% |
| Product Used For Unknown Indication |
3.0% |
| Drop Attacks |
2.9% |
| Status Epilepticus |
2.9% |
| Hypothyroidism |
2.5% |
| Arrhythmia |
2.3% |
| Multiple Allergies |
2.3% |
| Thyroid Hormone Replacement Therapy |
2.3% |
| Urticaria |
2.3% |
| Vitamin Supplementation |
2.3% |
| Myocardial Infarction |
2.2% |
| Breast Cancer |
1.9% |
| Convulsion Prophylaxis |
1.9% |
| Polyarthritis |
1.7% |
|
| Drug Interaction |
16.6% |
| Toxicity To Various Agents |
16.0% |
| Weight Decreased |
10.9% |
| Off Label Use |
5.7% |
| Therapeutic Agent Toxicity |
5.7% |
| Unresponsive To Stimuli |
5.1% |
| Diplopia |
4.6% |
| Drug Toxicity |
4.0% |
| Somnolence |
4.0% |
| Thrombocythaemia |
4.0% |
| Dizziness |
3.4% |
| Vertigo |
3.4% |
| Neurotoxicity |
2.9% |
| Thrombocytopenia |
2.9% |
| Status Epilepticus |
2.3% |
| Vomiting |
2.3% |
| Balance Disorder |
1.7% |
| Drug Level Decreased |
1.7% |
| Drug Level Increased |
1.7% |
| Anticonvulsant Drug Level Decreased |
1.1% |
|
